Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

GTHX

G1 Therapeutics (GTHX)

G1 Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:GTHX
FechaHoraFuenteTítuloSímboloCompañía
24/06/202405:30GlobeNewswire Inc.G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)NASDAQ:GTHXG1 Therapeutics Inc
14/06/202415:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GTHXG1 Therapeutics Inc
14/06/202415:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:GTHXG1 Therapeutics Inc
05/06/202406:00GlobeNewswire Inc.G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:GTHXG1 Therapeutics Inc
28/05/202405:30GlobeNewswire Inc.Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)NASDAQ:GTHXG1 Therapeutics Inc
23/05/202416:06GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingNASDAQ:GTHXG1 Therapeutics Inc
22/05/202409:00GlobeNewswire Inc.G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation SummitNASDAQ:GTHXG1 Therapeutics Inc
22/05/202405:30GlobeNewswire Inc.G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective UsesNASDAQ:GTHXG1 Therapeutics Inc
01/05/202405:30GlobeNewswire Inc.G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
01/05/202405:25GlobeNewswire Inc.G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for LerociclibNASDAQ:GTHXG1 Therapeutics Inc
17/04/202408:00GlobeNewswire Inc.G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024NASDAQ:GTHXG1 Therapeutics Inc
04/04/202409:30GlobeNewswire Inc.G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
28/02/202405:30GlobeNewswire Inc.G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
27/02/202407:30GlobeNewswire Inc.G1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:GTHXG1 Therapeutics Inc
15/02/202407:30GlobeNewswire Inc.G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024NASDAQ:GTHXG1 Therapeutics Inc
12/02/202415:42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GTHXG1 Therapeutics Inc
12/02/202415:05GlobeNewswire Inc.G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring CommitteeNASDAQ:GTHXG1 Therapeutics Inc
08/01/202405:45GlobeNewswire Inc.G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
03/01/202408:00GlobeNewswire Inc.G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:GTHXG1 Therapeutics Inc
05/12/202308:26GlobeNewswire Inc.G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer TherapyNASDAQ:GTHXG1 Therapeutics Inc
29/11/202319:37GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer SymposiumNASDAQ:GTHXG1 Therapeutics Inc
01/11/202315:37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:GTHXG1 Therapeutics Inc
01/11/202315:02Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:GTHXG1 Therapeutics Inc
01/11/202305:30GlobeNewswire Inc.G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:GTHXG1 Therapeutics Inc
27/10/202306:00GlobeNewswire Inc.Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)NASDAQ:GTHXG1 Therapeutics Inc
18/10/202307:00GlobeNewswire Inc.G1 Therapeutics’ COSELA® (trilaciclib) Recommended in Updated Small Cell Lung Cancer Guidelines from the American Society of Clinical Oncology (ASCO)NASDAQ:GTHXG1 Therapeutics Inc
18/10/202306:30GlobeNewswire Inc.G1 Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 1, 2023NASDAQ:GTHXG1 Therapeutics Inc
16/10/202308:00GlobeNewswire Inc.G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care SymposiumNASDAQ:GTHXG1 Therapeutics Inc
18/09/202306:00GlobeNewswire Inc.Black Diamond Therapeutics Announces CEO TransitionNASDAQ:GTHXG1 Therapeutics Inc
05/09/202310:00GlobeNewswire Inc.G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:GTHXG1 Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:GTHX

Su Consulta Reciente

Delayed Upgrade Clock